World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
79
Citations
21098
World Ranking
17644
National Ranking
8814

Albert B. Deisseroth publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Albert B. Deisseroth sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 342 publications — 26th percentile

26% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Albert B. Deisseroth D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Albert B. Deisseroth sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 79 D-Index — 14th percentile

14% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Albert B. Deisseroth is affiliated with the US Food and Drug Administration in the United States. Their research primarily focuses on the medical and hematological fields, with a particular emphasis on acute myeloid leukemia and related areas.

The main fields of study in Deisseroth's work include Medicine, with more specialized subfields in Hematology, Molecular Biology, Biochemistry, Oncology, and Genetics. This highlights a multidisciplinary approach to understanding blood cancers and their molecular and genetic underpinnings.

The scientific topics frequently addressed in their publications include:

  • Acute Myeloid Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Multiple Myeloma Research and Treatments
  • Retinoids in leukemia and cellular processes
  • Antioxidant Activity and Oxidative Stress
  • Neutropenia and Cancer Infections
  • Myeloproliferative Neoplasms: Diagnosis and Treatment

Deisseroth has co-authored multiple papers with several researchers, with the most frequent collaborators being Kelly J. Norsworthy, Ann T. Farrell, R. Angelo de Claro, Richard Pazdur, and Rajeshwari Sridhara. These collaborations indicate a network of ongoing research partnerships primarily concentrating on oncology and hematology.

Research outputs from Deisseroth can be found in notable publication venues, including:

  • Clinical Cancer Research
  • Leukemia
  • Journal of Clinical Oncology

Three recent papers attributed to Deisseroth cover various important aspects of leukemia research and treatment:

  • Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis (2020), published in Clinical Cancer Research
  • Second cancers in adults with acute promyelocytic leukemia treated with or without arsenic trioxide: a SEER-medicare analysis (2020), published in Leukemia
  • Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses (2021), published in Journal of Clinical Oncology

Albert B. Deisseroth has been recognized as a member of the Association of American Physicians, marking a formal acknowledgment within the medical community.

Best Publications

  • Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression.

    L B Owen-Schaub;W Zhang;J C Cusack;L S Angelo

  • Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML.

    Albert B. Deisseroth;Zhifei Zu;David Claxton;Elie G. Hanania

  • Allogeneic Blood Stem Cell Transplantation for Refractory Leukemia and Lymphoma: Potential Advantage of Blood Over Marrow Allografts

    M Korbling;D Przepiorka;YO Huh;H Engel

  • Chronic myelogenous leukemia: a concise update

    H. M. Kantarjian;A. Deisseroth;R. Kurzrock;Z. Estrov

  • Cardiotoxicity Associated With High-Dose Cyclophosphamide Therapy

    John S. Gottdiener;Frederick R. Appelbaum;Victor J. Ferrans;Albert Deisseroth

  • CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation

    S. Giralt;J. Hester;Yang O Huh;Cheryl F Hirsch-Ginsberg

  • Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease.

    Martin Korbling;Yang O Huh;A. Durett;N. Mirza

  • Considerations in the development of circulating tumor cell technology for clinical use

    David R Parkinson;Nicholas Dracopoli;Brenda Gumbs Petty;Carolyn Compton

  • Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma

    Frederick R. Appelbaum;Geoffrey P. Herzig;John L. Ziegler;Robert G. Graw

  • A novel interferon-inducible domain: structural and functional analysis of the human interferon regulatory factor 1 gene promoter.

    S. H. Sims;Ying Cha;M. F. Romine;Pei-Qing Gao

  • Localization of the human α-globin structural gene to chromosome 16 in somatic cell hybrids by molecular hybridization assay

    Albert Deisseroth;Arthur Nienhuis;Patricia Turner;Ramon Velez

  • Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions

    Daniel G. Wright;Kathleen J. Robichaud;Philip A. Pizzo;Albert B. Deisseroth

  • Duration of empiric antibiotic therapy in granulocytopenic patients with cancer

    Philip A Pizzo;Kay J Robichaud;Fred A Gill;Frank G Witebsky

  • p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation

    Wei Zhang;Luigi Grasso;Luigi Grasso;Craig D. McClain;Anne M. Gambel

  • U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma

    Thomas Herndon;Albert B Deisseroth;Edvardas Kaminskas;Robert C Kane

  • Scleroderma, Sjögren-like Syndrome, and Chronic Graft-Versus-Host Disease

    Thomas J. Lawley;Gary L. Peck;Haralampos M. Moutsopoulos;Alois A. Gratwohl

  • Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma.

    Gabriel N. Hortobagyi;Aman U Buzdar;Richard L. Theriault;Vicente Valero

  • Expression of unusual immunophenotype combinations in acute myelogenous leukemia.

    Christopher L. Reading;Elihu H. Estey;Yang O. Huh;David F. Claxton

  • Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups

    P.B McGlave;P De Fabritiis;A Deisseroth;J Goldman

  • Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor.

    C. F. LeMaistre;C. Meneghetti;M. Rosenblum;J. Reuben

Frequent Co-Authors

Richard E. Champlin
Richard E. Champlin The University of Texas MD Anderson Cancer Center
Moshe Talpaz
Moshe Talpaz University of Michigan–Ann Arbor
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Michael Andreeff
Michael Andreeff The University of Texas MD Anderson Cancer Center
Borje S. Andersson
Borje S. Andersson The University of Texas MD Anderson Cancer Center
Donna Przepiorka
Donna Przepiorka US Food and Drug Administration
wei zhang
wei zhang Wake Forest University
Issa F. Khouri
Issa F. Khouri The University of Texas MD Anderson Cancer Center
Sergio Giralt
Sergio Giralt Memorial Sloan Kettering Cancer Center
Steven M. Kornblau
Steven M. Kornblau The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in medicine but seeking alternative or supplementary careers, there are several flexible online degree options. Fields such as pharmacy, health information, medical billing, and nursing offer diverse opportunities and can be pursued virtually from anywhere in the U.S.

Those considering pharmaceutical careers may explore online pharmd programs to earn a doctorate without leaving their job or relocating. Similarly, health information management professionals are in demand to oversee patient data, and pursuing an online mhi can open doors in this growing field.

If you’re looking for a shorter, skills-focused route, the average cost of medical billing and coding program is often much lower than traditional 4-year degrees, making it an accessible entry into healthcare administration.

Aspiring advanced practice nurses can also benefit from cheap np programs, which allow working nurses to upgrade their qualifications online without significant financial burden. These pathways let you tailor your medical career to your interests, schedule, and budget.

Best Scientists Citing Albert B. Deisseroth

Trending Scientists

Recently Published Articles